

**Staphylococcus aureus, Strain HIP08926**

**Catalog No. NR-45873**

**Product Description:** *Staphylococcus aureus* (*S. aureus*), strain HIP08926 was isolated in 2000 from a bone or joint of a 72-year-old female patient in California, USA. *S. aureus*, strain HIP08926 is a vancomycin-intermediate *S. aureus* (VISA) strain.

**Lot<sup>1</sup>: 63406784**

**Manufacturing Date: 01APR2015**

TEST	SPECIFICATIONS	RESULTS
<b>Phenotypic Analysis</b> Cellular morphology Colony morphology <sup>2</sup>  Motility (wet mount) Hemolysis <sup>2</sup> Biochemical Characterization Catalase Coagulase <sup>4</sup> VITEK <sup>®</sup> 2 Compact (GP card)	Gram-positive cocci Report results  Report results Report results  Positive Report results Consistent with <i>S. aureus</i>	Gram-positive cocci Circular, low convex, entire, smooth and cream (Figure 1) Non-motile Non-hemolytic <sup>3</sup>  Positive Positive Consistent with <i>S. aureus</i>
<b>Antibiotic Susceptibility Profile</b> VITEK <sup>®</sup> (AST-GP71 card) <sup>5</sup> Beta-lactamase <sup>6</sup> Cefoxitin screen Benzylpenicillin Oxacillin Gentamicin Ciprofloxacin Levofloxacin Moxifloxacin Clindamycin (inducible resistance) Erythromycin Clindamycin Quinupristin/dalfopristin Linezolid Daptomycin Vancomycin Minocycline Tetracycline Tigecycline Nitrofurantoin Rifampicin Trimethoprim/sulfamethoxazole Etest <sup>®</sup> antibiotic test strips <sup>8</sup> Chloramphenicol <sup>9</sup> Teicoplanin <sup>9</sup>	Report results Report results Report results Resistant Sensitive Resistant Report results Report results Report results Report results Report results Report results Report results Non-susceptible Intermediate Report results Sensitive Report results Report results Report results Report results Report results Resistant  Report results Sensitive	Positive Positive Resistant ( $\geq 0.5 \mu\text{g/mL}$ ) Resistant ( $\geq 4 \mu\text{g/mL}$ ) Sensitive ( $\leq 0.5 \mu\text{g/mL}$ ) Resistant ( $\geq 8 \mu\text{g/mL}$ ) Resistant ( $= 4 \mu\text{g/mL}$ ) Resistant ( $= 2 \mu\text{g/mL}$ ) Negative Resistant ( $\geq 8 \mu\text{g/mL}$ ) Resistant ( $\geq 8 \mu\text{g/mL}$ ) Sensitive ( $= 0.5 \mu\text{g/mL}$ ) Sensitive ( $= 2 \mu\text{g/mL}$ ) Non-susceptible ( $= 2 \mu\text{g/mL}$ ) Sensitive ( $= 2 \mu\text{g/mL}$ ) <sup>7</sup> Sensitive ( $\leq 0.5 \mu\text{g/mL}$ ) Sensitive ( $\leq 1 \mu\text{g/mL}$ ) Sensitive ( $\leq 0.12 \mu\text{g/mL}$ ) Sensitive ( $\leq 16 \mu\text{g/mL}$ ) Sensitive ( $\leq 0.5 \mu\text{g/mL}$ ) Resistant ( $\geq 160 \mu\text{g/mL}$ )  Sensitive ( $= 3 \mu\text{g/mL}$ ) Sensitive ( $= 6 \mu\text{g/mL}$ )
<b>Genotypic Analysis</b> Sequencing of 16S ribosomal RNA gene (~ 1500 base pairs)	Consistent with <i>S. aureus</i>	Consistent with <i>S. aureus</i>
<b>Purity (post-freeze)<sup>10</sup></b>	Growth consistent with <i>S. aureus</i>	Growth consistent with <i>S. aureus</i>
<b>Viability (post-freeze)<sup>2</sup></b>	Growth	Growth

<sup>1</sup>*S. aureus*, strain HIP08926 was deposited to BEI Resources as part of the NARSA collection. NR-45873 was produced by inoculation of the deposited material into Tryptic Soy broth and grown 24 hours at 37°C in an aerobic atmosphere. Broth inoculum was added to Tryptic Soy agar with 5% defibrinated sheep blood kolles which were grown 23 hours at 37°C in an aerobic atmosphere to produce this lot.

<sup>2</sup>21 hours at 37°C in an aerobic atmosphere on Tryptic Soy agar with 5% defibrinated sheep blood

<sup>3</sup>Limited β-hemolysis may be observed

<sup>4</sup>4 hours at 37°C in rabbit serum with 0.15% EDTA (Coagulase Plasma BBL™ 240827)

<sup>5</sup>Minimum Inhibitory Concentration (MIC); MIC Interpretation Guideline: CLSI M100-S22 (2012)

<sup>6</sup>The production of beta-lactamase was detected using a Cefinase™ Paper Disc (BBL™ 231650).


<sup>7</sup>*S. aureus*, strain HIP08926 was deposited as susceptible to vancomycin with a MIC of 4 ug/mL. Based on CLSI M100-S22 (2012) MIC Interpretation Guidelines, a vancomycin MIC of 4 ug/mL is considered to be intermediate. Antibiotic susceptibility testing performed by ATCC® and in duplicate determined that strain HIP08926 is susceptible to vancomycin. For additional information on susceptibility testing of VISA strains, please refer to Wootton, M., et al. "A Modified Population Analysis Profile (PAP) Method to Detect Hetero-Resistance to Vancomycin in *Staphylococcus aureus* in a UK Hospital." *J. Antimicrob. Chemother.* 47 (2001): 399-403. PubMed: 11266410.

<sup>8</sup>24 hours at 37°C in an aerobic atmosphere on Mueller Hinton agar

<sup>9</sup>For both chloramphenicol (bioMérieux Etest® 412308) and teicoplanin (bioMérieux Etest® 412459), a MIC ≤ 8 µg/mL is sensitive, a MIC = 16 µg/mL is intermediate, and a MIC ≥ 32 µg/mL is resistant.

<sup>10</sup>Purity of this lot was assessed for 7 days on Tryptic Soy agar with 5% defibrinated sheep blood at 37°C in an aerobic atmosphere.

Figure 1



Date: 05 JUN 2015

Signature:

BEI Resources Authentication

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

ATCC® is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

